Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.

Archive ouverte

Pasquier, David | Bidaut, L. | Oprea-Lager, D. E. | Desouza, N. M. | Krug, D. | Collette, L. | Kunz, W. | Belkacemi, Y. | Bau, M. G. | Caramella, C. | de Geus-Oei, L. F. | de Caluwé, A. | Deroose, C. | Gheysens, O. | Herrmann, K. | Kindts, I. | Kontos, M. | Kümmel, S. | Linderholm, B. | Lopci, E. | Meattini, I. | Smeets, A. | Kaidar-Person, O. | Poortmans, P. | Tsoutsou, P. | Hajjaji, Nawale | Russell, N. | Senkus, E. | Talbot, J. N. | Umutlu, L. | Vandecaveye, V. | Verhoeff, J. J. C. | van Oordt, W. M. H. | Zacho, H. D. | Cardoso, F. | Fournier, L. | van Duijnhoven, F. | Lecouvet, F. E.

Edité par CCSD ; Elsevier -

International audience. Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease and clinical trials of oligometastatic breast cancer. After an exhaustive review of the literature covering all aspects of oligometastatic breast cancer, 35 experts from the European Organisation for Research and Treatment of Cancer Imaging and Breast Cancer Groups elaborated a Delphi questionnaire aimed at offering consensus recommendations, including oligometastatic breast cancer definition, optimal diagnostic pathways, and clinical trials required to evaluate the effect of diagnostic imaging strategies and metastasis-directed therapies. The main recommendations are the introduction of modern imaging methods in metastatic screening for an earlier diagnosis of oligometastatic breast cancer and the development of prospective trials also considering the histological and molecular complexity of breast cancer. Strategies for the randomisation of imaging methods and therapeutic approaches in different subsets of patients are also addressed.

Consulter en ligne

Suggestions

Du même auteur

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Archive ouverte | Gourgou-Bourgade, Sophie | CCSD

International audience. BACKGROUND: Using surrogate end points for overall survival, such as disease-free survival, is increasingly common in randomized controlled trials. However, the definitions of several of thes...

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Archive ouverte | Cardoso, F. | CCSD

International audience

Erratum to “Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Archive ouverte | Cardoso, F. | CCSD

International audience

Chargement des enrichissements...